Patent intelligence · US
US 10034866
Inhalable medicament comprising tiotropium
Inhalable medicament comprising tiotropium
Patent details — US 10034866
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 31, 2018
- Expiration
- Jul 26, 2038
- Claims
- 6
- CPC classes
- A61K, A61K31/439, A61K47/10, A61K47/12
Quick answer
US 10034866 (Inhalable medicament comprising tiotropium) is held by Teva Branded Pharmaceutical Products R&D, Inc.. Status: granted. Granted Jul 31, 2018. Expires Jul 26, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 6
- CPC classes
- A61K, A61K31/439, A61K47/10, A61K47/12, A61K9/008
More from Teva Branded Pharmaceutical Products R&D, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 10034866?
US 10034866 (Inhalable medicament comprising tiotropium) is held by Teva Branded Pharmaceutical Products R&D, Inc.. Status: granted. Granted Jul 31, 2018. Expires Jul 26, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10034866?
Teva Branded Pharmaceutical Products R&D, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 10034866 expire?
Our index shows an expiration date of Jul 26, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.